公开(公告)号：US11261236B2

公开(公告)日：2022-03-01

申请号：US16475955

申请日：2018-01-04

申请人： Kyungpook National University Industry-Academic Cooperation Foundation

发明人： Soyoun Kim ,  Jun Young Seo ,  In San Kim

IPC分类号： C07K14/79 ,  A61K47/66 ,  C07K7/06 ,  C07K14/745 ,  C12N9/68 ,  A61K38/00

摘要： The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide; and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide are sequentially linked; a composition for preventing or treating thrombotic disorders, containing the same as an active ingredient; a method for treating thrombotic disorders; and a therapeutic use. According to the present invention, CLT-sFt-μPn DCNC as a novel plasmin-based thrombolytic nanocage has: an effect of targeting a site at which thrombus is present; a low sensitivity to inhibitors present in the circulatory system; pharmacological activity strongly destroying both arterial and venous thrombi; and no side effects of bleeding, and thus can be very useful in developing an agent for preventing or treating thrombotic disorders.

公开(公告)号：US20210106657A1

公开(公告)日：2021-04-15

申请号：US17130340

申请日：2020-12-22

申请人： PROMETIC BIOTHERAPEUTICS, INC.

发明人： DAVIDA BLACKMAN ,  STACY PLUM ,  WILLIAM GARZON-RODRIGUEZ ,  MARTIN ROBITAILLE ,  BETTY YU

IPC分类号： A61K38/48 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  C12N9/68 ,  A61K9/00 ,  A61K9/08

摘要： Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 μm which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

公开(公告)号：US20200155706A1

公开(公告)日：2020-05-21

申请号：US16577734

申请日：2019-09-20

申请人： ModernaTX, Inc.

发明人： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC分类号： A61K48/00 ,  C12P21/00 ,  C07K16/00 ,  C07K14/515 ,  A61K38/48 ,  A61K38/21 ,  A61K38/19 ,  A61K38/18 ,  A61K9/51 ,  A61K9/14 ,  A61K47/54 ,  C12N9/64 ,  C12N9/68 ,  C12N9/12 ,  C12N9/02 ,  C07K16/40 ,  C07K16/28 ,  C07K14/745 ,  C07K14/61 ,  C07K14/56 ,  C07K14/54 ,  C07K14/525 ,  C07K14/495 ,  C07K14/475 ,  C07K14/47 ,  C07K14/435 ,  C07H21/02 ,  C07K14/485 ,  A61K38/17 ,  C12N15/52 ,  C12N9/24 ,  C12N9/16 ,  C07K14/005 ,  A61K38/45 ,  C12P13/04 ,  C12N15/87 ,  C12N9/42 ,  C12N9/00 ,  C12N9/10 ,  C07K14/535 ,  C07K14/505 ,  C07K14/705 ,  C12N15/11 ,  A61K9/127 ,  C12N9/88 ,  A61K31/7115 ,  C07K14/62 ,  C12N15/85

摘要： The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US09814760B2

公开(公告)日：2017-11-14

申请号：US14878400

申请日：2015-10-08

申请人： ModernaTX, Inc.

发明人： Stephane Bancel ,  Tirtha Chakraborty ,  Antonin de Fougerolles ,  Sayda M. Elbashir ,  Matthias John ,  Atanu Roy ,  Susan Whoriskey ,  Kristy M. Wood ,  Paul Hatala ,  Jason P. Schrum ,  Kenechi Ejebe ,  Jeff Lynn Ellsworth ,  Justin Guild

IPC分类号： C07H21/02 ,  C12N15/85 ,  A61K38/17 ,  C07K14/47 ,  C07K14/62 ,  A61K48/00 ,  A61K31/7115 ,  C12N9/88 ,  A61K9/127 ,  C12N15/11 ,  C07K14/705 ,  C07K14/505 ,  C07K14/535 ,  C12N9/64 ,  C12N9/10 ,  C12N9/00 ,  C12N9/42 ,  C12N15/87 ,  C12P13/04 ,  A61K38/45 ,  C07K14/005 ,  C12N9/16 ,  C12N9/24 ,  C12N15/52 ,  C07K14/435 ,  C12P21/00 ,  C07K14/485 ,  C07K14/475 ,  C07K14/495 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/745 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  C12N9/12 ,  C12N9/68 ,  A61K38/00

CPC分类号： A61K48/0066 ,  A61K9/1271 ,  A61K9/145 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/45 ,  A61K38/4846 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/43595 ,  C07K14/47 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/4723 ,  C07K14/4746 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5418 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/40 ,  C12N9/0069 ,  C12N9/0091 ,  C12N9/1051 ,  C12N9/1241 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/6435 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/6443 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y116/03001 ,  C12Y207/07012 ,  C12Y304/21007 ,  C12Y304/21022 ,  C12Y304/21027 ,  C12Y403/02001 ,  C12Y603/02019 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/423 ,  Y02A50/463 ,  Y02A50/491

摘要： The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20170044522A1

公开(公告)日：2017-02-16

申请号：US15337283

申请日：2016-10-28

申请人： BioAtla, LLC

发明人： Jay M. Short ,  Hwai Wen Chang ,  Gerhard Frey

IPC分类号： C12N15/10 ,  G01N33/68 ,  C12N9/68

CPC分类号： C12N15/102 ,  A61K38/00 ,  C07K7/06 ,  C07K14/3153 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57545 ,  C07K14/57563 ,  C12N9/16 ,  C12N9/50 ,  C12N9/6435 ,  C12N9/6459 ,  C12N9/6462 ,  C12N15/1058 ,  C12Y302/01035 ,  C12Y304/21007 ,  C12Y304/21069 ,  C12Y304/21073 ,  C12Y304/23015 ,  C12Y304/24029 ,  G01N33/54306 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/6854 ,  Y02A50/473

摘要： This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

摘要翻译： 本公开涉及从野生型正常生理条件下可逆地或不可逆地灭活的野生型蛋白质，特别是治疗性蛋白质产生条件活性生物蛋白质的方法。 例如，进化蛋白质在体温实际上是无活性的，但在较低温度下是活性的。

公开(公告)号：US20140044796A1

公开(公告)日：2014-02-13

申请号：US13984850

申请日：2012-02-10

申请人： Beate Kehrel ,  Martin Brodde

发明人： Beate Kehrel ,  Martin Brodde

IPC分类号： G01N33/68 ,  C12N9/68 ,  C12N9/64

CPC分类号： C12N9/6435 ,  A61K38/00 ,  C12N9/6489 ,  C12Y304/21007 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/6854 ,  G01N33/6893 ,  G01N33/6896 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/4709 ,  G01N2333/775 ,  G01N2333/922 ,  G01N2800/2814 ,  G01N2800/7047

摘要： The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives. Furthermore the invention includes substances to identify and methods to detect bio-films, a method to examine hemocompatibility of materials and a method to optimize therapeutical products, and to provide reagents microorganisms to charge with for more reliable diagnostics and quality control of biopharmaceuticals and identification substances for the screening for preliminary stages of amyloids that can be used for technical purposes.

摘要翻译： 本发明涉及检测和定量错误折叠的蛋白质/肽的领域。 特别是体液中人体和哺乳动物的细胞表面上错误折叠的蛋白质/肽的检测和定量，检测用于科学研究和/或诊断用途的试剂和药物或其添加剂的试剂中错误折叠的蛋白质/肽的检测 并且还涉及从用于科学研究和/或诊断目的的试剂和药物或其添加剂的试剂中去除错误折叠的蛋白质/肽。 此外，本发明包括用于鉴定和检测生物膜的方法的物质，检查材料的血液相容性的方法以及优化治疗产品的方法，以及提供试剂微生物进行充电以获得更可靠的生物药物和鉴定物质的诊断和质量控制 用于筛选可用于技术目的的淀粉样蛋白的初步阶段。

公开(公告)号：US20120189609A1

公开(公告)日：2012-07-26

申请号：US13392623

申请日：2010-08-27

申请人： Jean-Marie Stassen ,  Ingeborg Stalmans

发明人： Jean-Marie Stassen ,  Ingeborg Stalmans

IPC分类号： A61K38/48 ,  A61P31/12 ,  A61P27/08 ,  A61P27/02 ,  A61P23/02 ,  C12N9/68 ,  A61P29/00

CPC分类号： A61K38/484 ,  A61K9/0048 ,  A61K9/0051 ,  A61K45/06 ,  A61K47/12

摘要： The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these.

摘要翻译： 本发明涉及小梁切除术手术的改进。 改进更具体地在于通过小梁切除术手术产生的巩膜 - 角膜引流通道的延长的使用寿命。 改善是通过手术后施用单独的局部眼药水的形式的纤溶酶或其活性衍生物，通过单独的前房注射或其任意组合来获得的。

公开(公告)号：US20090181007A1

公开(公告)日：2009-07-16

申请号：US12296850

申请日：2007-04-12

申请人： Luisa Gennero ,  Antonio Ponzetto ,  Enrico De Vivo ,  Luciano Contu ,  Emanuella Morra ,  Chiara Cesano ,  Giovanni Cavallo ,  Giuseppe Cicero ,  Gian Piero Pescarmona ,  Tetyana Denysenko ,  Maria Augusta Roos ,  Maurizio Sara

发明人： Luisa Gennero ,  Antonio Ponzetto ,  Enrico De Vivo ,  Luciano Contu ,  Emanuella Morra ,  Chiara Cesano ,  Giovanni Cavallo ,  Giuseppe Cicero ,  Gian Piero Pescarmona ,  Tetyana Denysenko ,  Maria Augusta Roos ,  Maurizio Sara

IPC分类号： A61K38/48 ,  C12N5/00 ,  C12N5/02 ,  C12N9/00 ,  C12N9/50 ,  C12N9/48 ,  C12N9/22 ,  C12N9/66 ,  C12N9/68 ,  C12N9/52 ,  C12N9/62 ,  A61K38/46 ,  A61P43/00

CPC分类号： C12N5/0655 ,  A61L27/3817 ,  A61L27/3852 ,  A61L27/3895 ,  A61L2430/06 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2501/15 ,  C12N2501/235 ,  C12N2501/33 ,  C12N2502/1358

摘要： A composition for in vitro use as a culture medium or in vivo use as a pharmaceutical composition or a medical device, capable of accelerating the differentiation of stem cells into cells with a chondrocytic phenotype and of restoring the original trophism of chondrocytes, is described. The composition comprises, in combination, at least one proteolytic enzyme, at least one growth factor and at least one from a sugar, an amino acid, a vitamin factor, a vitamin, a nucleotide and a nucleoside, in a physiologically acceptable carrier or diluent. A method of differentiating stem cells in cells having a chondrocytic phenotype, the cells obtained by the method and their uses, for example in human or animal cell therapy, for example by CBMP (Cellular Based Medicinal products) are also described.

摘要翻译： 描述了用于体外用作培养基或体内用作药物组合物或医疗装置的组合物，其能够加速干细胞分化成具有软骨细胞表型的细胞并恢复软骨细胞的原始营养。 组合物在生理上可接受的载体或稀释剂中组合包含至少一种蛋白水解酶，至少一种生长因子和至少一种来自糖，氨基酸，维生素因子，维生素，核苷酸和核苷的组合物 。 还描述了在具有软骨细胞表型的细胞中分化干细胞的方法，通过该方法获得的细胞及其用途，例如在人或动物细胞治疗中，例如通过CBMP（基于细胞的药物产品）。

公开(公告)号：US07544500B2

公开(公告)日：2009-06-09

申请号：US10692105

申请日：2003-10-23

申请人： Rita T. Bradley ,  Scott A. Cook ,  Christopher A. Dadd ,  Jonathan D. Kent ,  Marina N. Korneyeva ,  Valery V. Novokhatny ,  James F. Rebbeor ,  Christopher J. Stenland ,  Jonathan S. Strauss ,  Jarrett C. Terry ,  Jeffrey A. Yuziuk

发明人： Rita T. Bradley ,  Scott A. Cook ,  Christopher A. Dadd ,  Jonathan D. Kent ,  Marina N. Korneyeva ,  Valery V. Novokhatny ,  James F. Rebbeor ,  Christopher J. Stenland ,  Jonathan S. Strauss ,  Jarrett C. Terry ,  Jeffrey A. Yuziuk

IPC分类号： C12N9/50 ,  C12N9/68 ,  C12N9/70

CPC分类号： A61K38/4833 ,  A61K38/484 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C12N9/6435 ,  C12Y304/21007

摘要： Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.

摘要翻译： 本发明公开了通过活化纤溶酶原产生可逆失活的酸化纤溶酶的方法和用于产生纯化的纤溶酶原的方法。 分离产生的纤溶酶并用低pH缓冲能力试剂储存以提供基本上稳定的制剂。 纯化的纤溶酶原通常从从级分II + III色谱法分离免疫球蛋白获得的级分中纯化，并在低pH下洗脱。 可逆惰性的酸化纤溶酶可以用于溶栓治疗的施用。

公开(公告)号：US20050124036A1

公开(公告)日：2005-06-09

申请号：US10503910

申请日：2003-02-06

申请人： Rudy Susilo ,  Hans Korting ,  Hans Gassen ,  Martin Hils ,  Ralf Pasternack

发明人： Rudy Susilo ,  Hans Korting ,  Hans Gassen ,  Martin Hils ,  Ralf Pasternack

IPC分类号： C12N15/09 ,  A61K9/06 ,  A61K9/70 ,  A61K31/616 ,  A61K31/727 ,  A61K38/43 ,  A61K38/48 ,  A61K45/00 ,  A61P7/00 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P17/02 ,  A61P27/02 ,  C08B37/10 ,  C12N1/15 ,  C12N1/19 ,  C12N9/68 ,  C12N15/57 ,  C12N15/62 ,  C12Q1/37 ,  C07H21/04 ,  C12N1/18 ,  C12N9/48 ,  C12N15/74 ,  C12P21/04

CPC分类号： C12N9/6435 ,  C07K2319/02 ,  C12N15/62 ,  C12Y304/21007

摘要： The invention relates to a method for producing a recombinant functional plasminogen in micro-organisms, and to a method for identifying plasminogen activators. The nucleic acid sequence coding for the fuctional part of the plasminogen is fused with a nucleic acid molecule coding for at least one signal peptide. The nucleic acid molecule coding for the plasminogen and the nucleic acid molecule coding for the signal peptide are combined with codons for interfaces of proteases which ensure the separation of the signal peptide. The recombinant plasminogen or the corresponding plasmin is suitable for treating wounds which are slow to heal or not healing, by application of the enzyme in an appropriate formulation.

摘要翻译： 本发明涉及一种用于在微生物中产生重组功能性纤溶酶原的方法和一种鉴定纤溶酶原激活物的方法。 编码纤溶酶原功能部分的核酸序列与编码至少一个信号肽的核酸分子融合。 编码纤溶酶原的核酸分子和编码信号肽的核酸分子与保证信号肽分离的蛋白酶界面的密码子组合。 重组纤溶酶原或相应的纤溶酶适合于通过在合适的制剂中施用酶来治疗慢愈合或不愈合的伤口。